Das Medizinportal
Menü

Literatur:

SCHWERPUNKT: ASCO/PERSONALISIERTE TUMORTHERAPIE

ASCO-Highlights zur GI-Onkologie (S. 25–29)

Thomas Seufferlein

 

  1. Kudo et al. Lancet 2018; 391: 1163–117
  2. El-Khoueiry et al. Lancet 2017; 389: 2492–2502
  3. Zhu AX, et al. J Clin Oncol 2018; 36(suppl): abstr 4003
  4. Neoptolemos et al. Lancet 2017, 389; 1011–1024
  5. Conroy T, et al. J Clin Oncol 2018; 36(suppl): abstr LBA4001
  6. Van Tienhoven, et al. J Clin Oncol 2018; 36(suppl): abstr LBA4002
  7. Dahan L, et al. J Clin Oncol 2018; 36(suppl): abstr 4000
  8. Pietrantonio F, et al. J Clin Oncol 2018; 36(suppl): abstr 3505
  9. Geissler M, et al. J Clin Oncol 2018; 36(suppl): abstr 3509
  10. Quenet F, et al. J Clin Oncol 2018; 36(suppl): abstr LBA3503

 

UPDATE:
Aktueller Stand der Therapie des Nicht-kleinzelligen Lungenkarzinoms (S. 41–47)
Wolfgang M. Brückl

  1. www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Lungenkarzinom/LL_Lungenkarzinom_Langversion_1.0.pdf (Zugriff am 17.06.2018)
  2. Reck M, Rabe K. Precision Diagnosis and Treatment for advanced non-small-cell lung cancer. N Engl J Med 2017; 377: 849–861
  3. Scheel AH, Dietel M, Heukamp LC, et al., Harmonized PD-L1 immunohistochemistry for pulmonary squamous cell and adenocarcinoma. Modern Pathology. 2016; 29: 1165–1172
  4. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1 positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823–1833
  5. Lopes G, Wu Y, Kudaba J et al. Pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced/metastatic NSCLC with a PD-L1 TPS > 1 %: open-label, phase 3 KEYNOTE-042 study. Proc ASCO 2018http://www.icd-code.de/suche/ops/code/8-982.html?sp=S8-982
  6. Gandhi L, Rodriguez-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastastic non-small-cell lung cancer. N Engl J Med 2018. DOI: 10.1056/NEJMoa1801005
  7. Paz-Ares L, Luft A, Tafreshi A. et al. KEYNOTE-407: phase 3 study of carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab for metastatic squamous NSCLC. Proc ASCO 2018http://www.icd-code.de/ops/code/8-98h.html
  8. Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378: 2288–2301
  9. Hellmann MD, Ciuleanu TE, Pluzanski A et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018; 378: 2093–2104
  10. Spigel DR, McCleod M, Hussein MA. CheckMate 153: randomized results of continuous 1-year fixed duration nivolumab in patients with advanced non-small cell lung cancer. Proc ESMO 2017
  11. Soria JC, Mauguen A, Reck M et al. Systematic review and meta-analysis of randomized, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2013; 24: 20–30
  12. Garon EB, ciuleanu TE, Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small cell lung cancer after disease progress on platinum-based therapy (REVEL). Lancet 2014; 384: 665–673
  13. Reck M, Kaiser R, Mellemgaard A et al. Docetaxel plus nintedanib versus docetaxel plus placebo in pateints with previously treated non-small cell lung cancer (LUME-Lung1): a phase 3, double-blind, randomized controlled trial. Lancet Oncol 2014; 15: 143–155
  14. Kris MG, Johnson BE, Berry LD et al. Using multiplexed assays of onocogenic drivers in lung cancers to targeted drugs. JAMA 2014; 311: 1998–2006
  15. Brueckl WM, Tufman A, Huber RM. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs. Expert Rev Anticancer Ther 2017; 17: 143–155
  16. Wu YL, Cheng Y, Zhou X et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small cell lung cancer (ARCHER 1050): a randomized, open-label, phase 3 trial. Lancet Oncol 2017; 18: 1454–1466
  17. Soria JC, Ohe Y, Vansteenkiste J et al. Osimertinib in untreated EGFR-mutated advanced non-small cell lung cancer. N Engl J Med 2018; 378: 113–125
  18. Brueckl WM. Treatment of choice in EGFR-mutant non-small-cell lung cancer. Lancet Oncol 2017; 18: 1425–1426
  19. Nakamura A, Inoue A, Morita S et al. Phase III study comparing gefitinib monotherapy to combination therapy with gefitinib, carboplatin, and pemetrexed for untreated patients with advanced non-small cell lung cancer with eGFR mutations (NEJ009). Proc ASCO 2018
  20. Peters S, Camidge DR, Shaw AT et al. Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017; 377: 829–838
  21. Antonia SJ, Villegas A, Daniel D et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377: 1919–1929
  22. Durm G, Althouse S, Sadiq A et al. Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III NSCLC. Proc ASCO 2018
  23. Zhong WZ, Wang Q, Mao WM et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJVUANT/CTONG1104): a randomized, open-label phase 3 study. Lancet Oncol 2018; 119: 139–148
  24. Forde PM, Chaft JE, Smith KN et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018; 378: 1976–1986
  25. Johnson M. Treatment for NSCLC: is chemotherapy here to stay? Proc ASCO 2018